Here is a detailed roundup of the most prominent insider transactions that were disclosed on Friday for U.S. equities, organized by reported buys and sells and drawing directly from the respective filings with the Securities and Exchange Commission.
Summary of top insider buys
Faeth Therapeutics, Inc. (NASDAQ:FTH) reported that Chief Financial Officer Brian C. Stephenson purchased common stock with an aggregate value of $401,268 across two separate days, June 24 and June 26, 2026, according to a Form 4 filed with the SEC. The filings show Mr. Stephenson acquired a total of 15,641 shares at transaction prices ranging from $23.61 to $27.77 per share. The reported per-share purchase prices sit modestly above the stock's then-current trading price reported as $23.28. Those filings indicate the purchases were made indirectly, through the Brian Stephenson Revocable Trust, of which Mr. Stephenson serves as sole trustee and over which he retains sole voting and investment power. The filing states Mr. Stephenson disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.
CarMax Inc. (NASDAQ:KMX) saw two separate director-level buying disclosures. Director Mark F. O'Neil acquired $502,656 of common stock on June 24, 2026, with the filing showing purchases at $52.36 per share. The reported activity was split into two transactions: Mr. O'Neil directly bought 4,800 shares, and an additional 4,800 shares were acquired indirectly by The Mark F. O'Neil Family Irrevocable GST Trust, both at the same per-share price. At the time of the filing the stock was noted as trading close to $52.70 and having returned 35% over the prior six months, with the company carrying a market capitalization cited as $7.43 billion in the disclosure.
Also at CarMax, director Sona Chawla disclosed a purchase on June 25, 2026, acquiring 2,000 shares of common stock at $53.39 per share, for a total outlay of $106,780. Post-transaction, the filing reports Ms. Chawla directly owns 21,702 shares of CarMax common stock. The disclosure reiterates the stock's recent momentum, trading near $52.70 and up roughly 35% over the prior six months, and references an InvestingPro note that the company is slightly overvalued relative to its Fair Value. The filing further records the company trading at a P/E ratio of 33.86 times earnings and having a $7.4 billion market capitalization.
Tortoise Energy Infrastructure Corp (NASDAQ:TYG) disclosed that director Conrad S. Ciccotello purchased common shares totaling $173,479 on June 25, 2026. Mr. Ciccotello acquired 4,107 shares at a per-share price of $42.24. The filing describes these as direct purchases by Mr. Ciccotello.
Cross Timbers Royalty Trust (NASDAQ:CRT) reported purchases by a ten percent owner, SoftVest, LP, which bought a total of 7,774 units of beneficial interest for approximately $68,142 across two transactions in late June. The filing shows SoftVest acquired 4,047 units on June 24 at a weighted average price of $8.66 per unit, with component trades priced between $8.65 and $8.67. On June 25, SoftVest added 3,727 units at a weighted average price of $8.88 per unit, with individual trades at $8.87 to $8.88.
Summary of top insider sells
Broadcom Inc. (NASDAQ:AVGO) disclosed a large-scale disposal by director Henry Samueli in a Form 4 filing. The filing shows Mr. Samueli sold a total of 694,241 shares of Broadcom common stock on June 24, 2026, under a Rule 10b5-1 trading plan that was adopted on December 16, 2025. The sales occurred at prices ranging from $377.10 to $388.50 per share and the filing reports aggregate proceeds of $250,005,851. The sales were carried out indirectly through entities D95GT LLC and H&S Investments I, L.P., and the filing indicates Mr. Samueli disclaims beneficial ownership except to the extent of his pecuniary interest.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) disclosed that a group of affiliated investment funds and accounts, including Biotechnology Value Fund, L.P. and Biotechnology Value Fund II, L.P., among others, sold a block of common stock totaling 1,630,658 shares on June 26, 2026. All shares were sold at $106.50 per share, producing proceeds the filing lists as approximately $173.7 million. Following these transactions the filing reports that the affiliated funds and accounts continue to hold a substantial stake in the company. The disclosure also notes the stock had gained 136% over the prior year and was trading at $108, and references InvestingPro analysis stating the company appears overvalued relative to its Fair Value and carries a high Price/Book multiple of 6.24 while remaining unprofitable with a market capitalization of $8.87 billion.
Oracle Corp (NASDAQ:ORCL) vice chairman Jeffrey Henley sold 400,000 shares of common stock on June 24, 2026, pursuant to a Rule 10b5-1 plan adopted on January 2, 2026, according to the company's filing. Those sales occurred at prices ranging from $155.50 to $165.57 per share, with aggregate proceeds of about $63.7 million. The filing also indicates that prior to the sales Mr. Henley exercised stock options to acquire 400,000 shares at an exercise price of $40.93 per share, incurring a total exercise cost of $16,372,000; both the exercise and the subsequent sales were included in the trading plan adopted January 2, 2026.
Circle Internet Group, Inc. (NASDAQ:CRCL) reported that Chief Product and Technology Officer Nikhil Chandhok sold Class A common stock on June 24, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. The filing shows Mr. Chandhok sold 489,737 shares across multiple transactions to satisfy tax withholding obligations tied to the exercise of vested stock options. The per-share sale prices ranged from $70.83 to $75.36. The filing notes the stock traded at $73.57 at the time, and that it had declined 14% over the prior week and 68% over the past year. The disclosure includes an InvestingPro observation that the stock has suffered a substantial recent decline.
Best Buy Co Inc (NASDAQ:BBY) chairman emeritus Richard M. Schulze disclosed sales of 418,601 shares of common stock executed over two days, June 25 and June 26, 2026, in a Form 4 filing with the SEC. The filings show total proceeds of about $32.7 million, with weighted average sale prices cited between $78.1041 and $78.1321. On June 25 Mr. Schulze sold 193,896 shares at a weighted average price of $78.1321 per share, with individual trade prices between $78.00 and $78.57. On June 26 he sold 224,705 shares at a weighted average price of $78.1041 per share, with individual trade prices between $78.00 and $78.26. The filing indicates these sales were conducted indirectly through a revocable trust where Mr. Schulze serves as trustee. The filing notes Best Buy shares were trading at $77.71, up 18% year-to-date, and references InvestingPro commentary that classifies the stock among the Most Undervalued list and records a P/E ratio of 14.39, a PEG ratio of 0.45, and a dividend yield of 5%.
Context and observed patterns
The filed transactions display a mix of insider buying at smaller and mid-cap companies and sizable disposals by major shareholders and executives at larger enterprises. Reported purchases include both direct acquisitions and transactions executed indirectly through trusts. Several sales were conducted under Rule 10b5-1 plans, which the filings identify by adoption dates and which pre-schedule trades independent of subsequent company developments. A subset of sales, such as the Circle Internet Group disclosure, were reported specifically as actions to cover tax withholding tied to exercised options.
Where the filings and accompanying notes reference third-party analysis, those statements are presented as they appear in the disclosures. For example, the filings cite InvestingPro commentary for valuations and recent price performance: Faeth is noted to have delivered a 28% return over the past week and a 173% gain over the past year; CarMax is cited as having risen 35% over the last six months; Kymera is described as up 136% over the past year with valuation metrics suggesting overvaluation; and Best Buy is described as appearing undervalued with a P/E of 14.39 and a 5% dividend yield.
What investors should keep in mind
- Insider purchases can signal confidence from executives or directors, but the filings show a variety of purchase mechanics, including indirect holdings via trusts. Where the filings specify, individuals retain voting and investment power through trustee roles.
- Large sales executed under Rule 10b5-1 plans are pre-arranged and do not necessarily reflect a contemporaneous view of a company’s prospects at the time of the sale. Several filings explicitly reference the adoption dates of these plans.
- Certain disposals were identified as tax-related transactions tied to option exercises; the filings state those sales were intended to satisfy tax withholding obligations rather than to signal strategic reappraisals.
Detailed takeaways
The filings collectively illustrate how insiders and affiliated holders use a mix of direct purchases, trust-based acquisitions and pre-set sale plans to manage equity positions. Small- and mid-cap companies in the biotech and energy infrastructure space show insider buying from executives and directors. At larger-cap technology and retail firms, sizeable blocks of stock moved in planned sales, often through derivative or trust structures and frequently linked to option exercises or Rule 10b5-1 plans.
Investors referencing these filings should treat insider activity as one of multiple inputs when assessing risk and valuation; the disclosures themselves underscore that insiders sell for a range of reasons including diversification, tax planning and other personal financial considerations.
Key points
- Several executives and directors reported direct or trust-based purchases at companies including Faeth Therapeutics, CarMax and Tortoise Energy Infrastructure.
- Material sales were reported from high-profile names such as Broadcom, Kymera Therapeutics, Oracle, Circle Internet Group and Best Buy, some executed under pre-arranged Rule 10b5-1 plans.
- Filings include both operational details of trades and referenced valuation commentary from InvestingPro, highlighting differing views on relative valuation across names.
Risks and uncertainties highlighted in the filings
- Pre-scheduled sales under Rule 10b5-1 plans may not reflect current management sentiment; several large transactions disclosed were executed under such plans and thus may not indicate present views on company prospects. This affects perception in sectors including semiconductors, enterprise software and large-cap technology.
- Valuation commentary included in some filings points to overvaluation for certain stocks, notably Kymera Therapeutics, where InvestingPro analysis cited a high Price/Book multiple and the company remains unprofitable. This introduces valuation risk for biotech investors and related market participants.
- Insider sales made to cover tax obligations tied to option exercises, as disclosed for Circle Internet Group, illustrate liquidity-driven selling rather than an operational or strategic shift; this creates uncertainty around interpreting the motive for disposals, particularly in the fintech and cryptocurrency-adjacent sector.
Conclusion
The Friday filings show a mix of conviction buying by certain insiders at smaller and mid-sized issuers alongside significant, often pre-planned, sales by major holders and executives at larger companies. The disclosures reiterate that trades executed via trusts, option exercises and Rule 10b5-1 plans represent a variety of motivations and mechanics, and should be weighed alongside broader fundamental and valuation analysis when forming investment decisions.